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Intestinal APCs of the endogenous 
nanomineral pathway fail to 
express PD-L1 in Crohn’s disease
Jack Robertson1, Carolin T. Haas1, Laetitia C. Pele1, Tom P. Monie1, Charles Charalambos1, 
Miles Parkes2, Rachel E. Hewitt1 & Jonathan J. Powell1
Crohn’s disease is a chronic inflammatory condition most commonly affecting the ileum and colon. The 
aetiology of Crohn’s disease is complex and may include defects in peptidoglycan recognition, and/or 
failures in the establishment of intestinal tolerance. We have recently described a novel constitutive 
endogenous delivery system for the translocation of nanomineral-antigen-peptidoglycan (NAP) 
conjugates to antigen presenting cells (APCs) in intestinal lymphoid patches. In mice NAP conjugate 
delivery to APCs results in high surface expression of the immuno-modulatory molecule programmed 
death receptor ligand 1 (PD-L1). Here we report that NAP conjugate positive APCs in human ileal 
tissues from individuals with ulcerative colitis and intestinal carcinomas, also have high expression of 
PD-L1. However, NAP-conjugate positive APCs in intestinal tissue from patients with Crohn’s disease 
show selective failure in PD-L1 expression. Therefore, in Crohn’s disease intestinal antigen taken up by 
lymphoid patch APCs will be presented without PD-L1 induced tolerogenic signalling, perhaps initiating 
disease.
Crohn’s disease is a chronic and debilitating inflammatory condition of the ileum and colon that afflicts a growing 
proportion of the Western population. The precise cause of Crohn’s disease is unclear but dietary, lifestyle, genetic 
and pathogen related factors have all been proposed to be important1. Various genetic polymorphisms serve as 
risk factors for the development of Crohn’s disease, with specific mutations in the innate immune gene NOD2 
presenting the strongest single genetic risk factor2. How NOD2 mutation predisposes to disease is uncertain. It 
may involve aberrant signalling due to a failure to recognise peptidoglycan, defects in autophagy, disruption of 
other immune pathways, or alteration of the intestinal microbiota3–5.
Recently, we showed that Microfold (M) cells in murine ileal lymphoid patches are portals for the entry of 
endogenous luminally-formed nanomineral particles6. These nanomineral particles are composed of amorphous 
magnesium-substituted calcium phosphate templated around macromolecular luminal constituents, notably pro-
tein antigen and bacterial peptidoglycan, creating a nanomineral-antigen-peptidoglycan (NAP) conjugate. Once 
chaperoned across M cells, the luminally-derived peptidoglycan and protein antigen, still encased in their nano-
mineral shell, reach underlying APCs of the sub-epithelial dome where upon the nanomineral appears to readily 
release its peptidoglycan and protein cargo6. The NAP pathway ensures the safe chaperoning of cargo macromol-
ecules from lumen to APC and that cells receiving protein antigen are also the ones receiving peptidoglycan. This 
is particularly important as peptidoglycan, delivered in this fashion, provides a potent signal for APC surface 
expression of the immuno-inhibitory, co-regulatory molecule PD-L16,7. Indeed, in mice defective in intracellular 
peptidoglycan recognition there appears to be no expression of PD-L1 on intestinal APCs of the NAP pathway. In 
contrast, the same APCs of wild type mice are PD-L1hi 6.
PD-L1 provides a crucial immuno-inhibitory function. It is central to the development of regulatory T cells, 
via interaction with its receptor PD-1, and is normally upregulated during inflammation to restrain tissue dam-
age8. In the intestines PD-1 is usually expressed on activated T-cells in germinal centres of the Peyer’s Patches, 
whereas PD-L1 is found on macrophages and dendritic cells in the sub-epithelial dome9, as well as intestinal 
epithelial cells10. Physiological expression of PD-L1 has been shown to prevent antigen-induced inflammatory 
responses of the intestine11–13. Consequently, selective PD-L1 upregulation on APCs of the NAP pathway may 
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ensure that luminally-derived antigen is presented in a tolerogenic context to minimise intestinal inflammation. 
Given the above, and particularly the inability of Nod1 and Nod2 deficient mice to express PD-L1 on APCs 
in the NAP pathway6, we asked whether irregularities in PD-L1 expression could underpin the development 
and pathogenesis of Crohn’s disease. Analysis of ileal tissue samples revealed a dramatic cell selective defect in 
PD-L1 expression in Crohn’s disease. Specifically, nanomineral positive APCs of the NAP pathway almost ubiq-
uitously failed to express PD-L1 in samples from Crohn’s disease patients, but showed normal PD-L1 expression 
in controls. Consequently it is probable that in Crohn’s disease the majority of NAP-derived antigens, whether 
bacteria-derived or other luminal molecules, are not presented in a tolerogenic manner and thereby could con-
tribute to the development and exacerbation of an inflammatory response.
Results and Discussion
PD-L1 and Crohn’s disease. Regulated expression of PD-L1 is critical for the control of intestinal inflam-
mation12,13. We have previously shown that peptidoglycan can upregulate PD-L1 expression7 and that mice defi-
cient in Nod1 and Nod2 (cytoplasmic receptors for peptidoglycan) display defective PD-L1 expression in their 
intestinal APCs6. In addition, Crohn’s disease associated polymorphisms, including in NOD2, disrupt peptido-
glycan recognition7,14. We therefore hypothesised that defects in the delivery or recognition of peptidoglycan to 
APCs in the intestinal tract would result in aberrant PD-L1 expression and underpin the development of Crohn’s 
disease.
A comprehensive review of publically available CD274 gene expression data (CD274 encodes the PD-L1 pro-
tein) did not provide evidence of global changes in CD274 expression levels between Crohn’s disease and control 
intestinal tissue (Supplementary Figure 1 and Supplementary Tables 1–3). Only two studies, both looking at 
inflamed adult colonic Crohn’s disease tissues, identified any significant change in CD274 expression and in both 
cases expression was upregulated in the Crohn’s disease tissue (Supplementary Figure 1)15,16. Such gene expression 
data does not, however, discriminate at the level of the individual cell, leaving open the possibility that specific 
cell types within the ileum or colon could display greater disparity in either CD274 expression, or PD-L1 surface 
expression. Indeed slightly enhanced PD-L1 protein expression in epithelial cells and in lamina propria mononu-
clear cells has been reported in Crohn’s disease albeit without widespread validation17,18.
PD-L1 expression is detectable in Crohn’s disease ileal tissue. The ileum is the primary target for 
inflammation in the majority of cases of Crohn’s disease and possesses a complex cellular micro-environment 
with a carefully defined stratification of cell populations (Fig. 1A). To address potential cell-specific changes in 
PD-L1 surface expression we studied fresh human ileal tissue sections that had been snap-frozen from patients 
with and without Crohn’s disease. PD-L1 staining was detected in ileal epithelial cells by confocal microscopy 
irrespective of disease status (Fig. 1B). Some PD-L1 expression was also detectable in ileal lymphoid patches, 
showing a low to moderate level of expression in all samples (Fig. 1C). These findings corroborate the earlier gene 
analysis data showing that, as a whole, there is no lack of PD-L1 expression in Crohn’s disease gut tissue.
Nanomineral positive cells in Crohn’s disease tissues show a specific defect in PD-L1 expression. 
Intestinal lymphoid patches are a key site of intestinal antigen uptake in which M cells provide a specialised anti-
gen transportation function19. They also provide a focal point for aphthous ulcer-like lesion formation during the 
earliest microscopic signs of Crohn’s disease20. Staining for glycoprotein 2, an M cell specific surface marker21, 
confirmed the presence of M cells in the epithelium of the ileal lymphoid patches in both control and Crohn’s 
disease samples (Fig. 2A). M cells have recently been shown to be critical for the translocation of NAP-conjugates 
to underlying APCs6. This pathway remains functional in Crohn’s disease, as peptidoglycan co-localised with 
nanomineral positive cells (identified by calcein staining) are present in both control and Crohn’s disease tissues 
(Fig. 2B).
Interestingly, nanomineral positive cells of ileal lymphoid patches (i.e. cells involved in the NAP pathway6) 
showed a dramatic difference in PD-L1 expression between Crohn’s disease and control ileum (Fig. 2C). Control 
nanomineral positive cells were almost always positive for PD-L1 expression, whereas nanomineral positive cells 
from Crohn’s disease tissue were almost always negative for PD-L1 (Fig. 2C,D). To verify this observation we 
manually identified all nanomineral positive cells in our tissue samples and confirmed their PD-L1 status. A cell 
was defined as being both nanomineral and PD-L1 positive if discrete PD-L1 staining was also observed on the 
cell surface thereby avoiding false positives due to antibody adsorption to the nanomineral particles as previously 
described6 (see Methods and Supplementary Figure 2 for further details). In Crohn’s disease samples, only occa-
sional weak expression of PD-L1 was observed (n = 177 cells studied; 6 independent patients). In all control tis-
sues, PD-L1 was highly expressed on these same nanomineral positive cells (n = 191 cells studied; 9 independent 
patients) (p < 0.0004; Figs 2D and 3 and Table 1). The presence of PD-L1 expression on nanomineral positive cells 
from the ileum of patients with ulcerative colitis (Fig. 3 and Table 1) indicates that the aberrant phenotype is not 
a generalised phenomenon in inflammatory bowel conditions, but is specific to Crohn’s disease. This also implies 
that the NAP-pathway specific reduction in PD-L1 expression is not likely to be therapy-induced as both Crohn’s 
disease and ulcerative colitis patients had been receiving immunomodulatory medications. This is consistent with 
earlier studies showing that the steroid prednisone does not affect PD-L1 expression on plasmacytoid dendritic 
cells22 and that the suppression we observe is not seen across all cell types.
NOD2 polymorphisms are not the direct cause of defective PD-L1 expression in Crohn’s disease. 
Crohn’s disease is associated with polymorphisms in the NOD2 gene. The NOD2 protein is responsible for 
cytoplasmic detection of the peptidoglycan fragment muramyl dipeptide, and mice lacking Nod1 and Nod2 
appear to be defective in PD-L1 expression on APCs involved in the NAP pathway6. To check if NOD2 dys-
function alone could explain the defective PD-L1 expression in our Crohn’s disease samples we isolated DNA 
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from Crohn’s disease and control tissue samples and amplified sections of the NOD2 gene by PCR. These were 
sequenced to determine the presence, or absence, of the three most common Crohn’s disease-associated NOD2 
polymorphisms, namely R702W, G908R and L1007fsincC. Of our six Crohn’s disease tissue samples two were 
Figure 1. PD-L1 expression is detectable in both Crohn’s disease and control ileal tissue. (A) Schematic 
representation of the cellular organisation of the ileal region. The translocation of luminal antigens to APCs 
via the nanomineral-antigen-peptidoglycan (NAP) pathway is outlined. In brief, calcium and phosphate ions 
are secreted from epithelial cells back into the intestinal lumen where they mix with luminal molecules and 
subsequently precipitate forming nanoparticles which trap small quantities of food proteins and bacterial 
antigens. The resulting NAP conjugates are translocated from the lumen to the mucosa through M-cells and 
chaperoned APCs for uptake. Upon digestion of NAPs, peptidoglycan-induced PD-L1 is expressed on the APC 
surface and contributes to immune tolerance towards intestinal antigens. Typical confocal micrographs showing 
PD-L1 expression (red) in (B) epithelial cells and (C) ileal lymphoid patches from Crohn’s disease and control 
tissue sections. The ileal lymphoid patch is outlined in yellow. Scale bars are 50 μ m (B) and 150 μ m (C).
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heterozygous for G908R, one was heterozygous for L1007fsincC, one was heterozygous for both R702W and 
G908R, and two possessed none of the polymorphisms. Interestingly, one of the ulcerative colitis control samples 
was also heterozygous for L1007fsincC (Table 1). The diversity in polymorphism possession, the presence of 
L1007fsincC in one of the ulcerative colitis controls, and the lack of polymorphisms in two of the Crohn’s disease 
subjects, clearly supports that the aberrant expression of PD-L1 is not dictated directly by NOD2 genotype.
We further examined whether NOD2 genotype influences the induction of PD-L1 in peripheral cells when 
stimulated with either free peptidoglycan, or peptidoglycan contained in nanomineral particles (i.e nanoparticles 
of amorphous magnesium substituted calcium phosphate; AMCP). PBMCs from a new cohort of Crohn’s disease 
patients, heterozygous for NOD2 polymorphisms, and from healthy controls, responded in the same manner 
at both the gene and surface protein levels following stimulation (Fig. 4). In both populations stimulation of 
PBMCs with peptidoglycan-containing AMCP for 3 hours resulted in weak but significant upregulation of the 
CD274 gene after a further 5 hours incubation in control medium (Fig. 4A). Weak surface expression of PD-L1, 
but not PD-L2, was induced following cell stimulation with both soluble and particulate peptidoglycan (Fig. 4B). 
However, when using crude preparations of peptidoglycan from S. Aureus the levels of surface PD-L1 and PD-L2 
increased significantly in both control and Crohn’s disease cohorts (Fig. 4B). These observations fit with our 
previous work showing that PBMCs from Crohn’s disease patients homozygous for NOD2 L1007fsincC do not 
induce PD-L1 upon exposure to muramyl dipeptide, but they do so when stimulated with crude peptidoglycan 
in a manner presumed to be mediated by a receptor other than NOD2. In contrast, PBMCs from heterozygotes 
still responded to MDP by increasing PD-L1 expression7. Together these findings support our observations in 
intestinal tissue that the lack of PD-L1 expression in the NAP-pathway of Crohn’s disease patients is a cell (or 
site) specific phenomenon. This phenotype is consistent with that seen in murine cells defective in peptidoglycan 
processing6 and suggests that an inability to correctly ‘see’ peptidoglycan in Crohn’s disease results in aberrant 
expression of PD-L1 in APCs stimulated via the NAP pathway.
Collectively, our findings indicate that the APCs of the recently described NAP pathway of intestinal anti-
gen translocation display a selective failure in expression of PD-L1 in Crohn’s disease patients. Consequently 
these APCs could present the NAP-conjugate derived exogenous antigen, whether in the form of bacterial 
components or other luminal derived antigen, without concomitant negative co-stimulatory signalling. PD-L1 
is involved in the development of regulatory T cells and is sometimes up-regulated during inflammation to 
Figure 2. APCs in the NAP pathway show defective PD-L1 expression in Crohn’s disease. (A) Representative 
fluorescent micrographs showing M cells (identified by glycoprotein 2 staining; yellow) in the epithelium 
overlaying lymphoid patches in Crohn’s disease and control sections. Scale bars are 50 μ m. (B) Typical confocal 
micrographs demonstrating the presence of peptidoglycan (Pg; magenta) in nanomineral positive cells 
(identified by calcein; green) in both Crohn’s disease and control sections. Scale bars are 10 μ m. (C) Example 
confocal micrographs of Crohn’s disease and control ileal lymphoid patch cells showing that APCs from control 
tissue are both nanomineral (calcein-stained, green) and PD-L1 (red) positive, but Crohn’s disease associated 
APCs are nanomineral positive and PD-L1 negative. Scale bars are 10 μ m. (D) Percentage of nanomineral 
(calcein-stained) and PD-L1 positive cells in control and Crohn’s disease tissue (Crohn’s disease versus control: 
p < 0.0004 using the Mann-Whitney test). Data are shown as mean + SD. In all cases samples were tested from 
6 independent tissues for Crohn’s disease and 9 independent tissues for control tissues. In total 177 calcein 
(nanomineral) positive cells were identified in the Crohn’s disease samples, and 191 calcein (nanomineral) 
positive cells in the control tissues.
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Figure 3. Defective PD-L1 expression is limited to APCs from Crohn’s disease and is not observed in 
ulcerative colitis. Nanomineral positive cells (green) are only defective for PD-L1 (red) expression in Crohn’s 
disease. For each section all nanomineral (calcein) positive cells from the 63X micrograph were selected and 
expanded. Each cell was individually analysed and characterised as PD-L1 negative (Calcein+ PD-L1−) or 
PD-L1 positive (Calcein+ PD-L1+) as described in Materials and Methods. Panels (A) control tumour section, 
(B) control ulcerative colitis tissue section and (C) Crohn’s disease tissue section are representative of the 9 and 
6 tissue samples used for control and Crohn’s disease samples respectively. In each panel all identified calcein 
(nanomineral) positive cells are shown, regardless of their PD-L1 expression status.
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restrain tissue damage8. Indeed, PD-L1 expression prevented severe CD8+ T cell mediated autoimmune enteri-
tis in the iFABP-tOVA transgenic mouse model13. Our findings would explain not only the loss of tolerance 
to the luminal stream that is so commonly considered a hallmark of Crohn’s disease23, but also the observa-
tion that the earliest visible sign of Crohn’s disease manifests as microscopic ulceration that extends from 
the sub-epithelial dome of lymphoid patches20,24. The importance of PD-L1 in controlling intestinal inflam-
mation13,25 and the normal pattern of PD-L1 expression observed in ulcerative colitis ileum provides clear 
support for critical involvement of APCs from the NAP pathway in the maintenance of intestinal tolerance. 
The defective presentation of PD-L1 on NAP pathway APCs in Crohn’s disease may provide the missing link in 
the Crohn’s disease ‘road map’. By failing to upregulate PD-L1, APCs of the gut lymphoid tissue, which sample 
luminal peptidoglycan and antigen via the NAP pathway would present antigen in the absence of negative 
co-stimulation. Failure in PD-L1/PD-1 signalling combined with pro-inflammatory cytokine skewing leads 
to a gradual and general loss in tolerance towards antigen26–28. In this case, infection, or some other ‘adjuvant’ 
effect, could spark a local immuno-inflammatory response leading to the earliest disease signs of aphthoid 
ulceration of lymphoid aggregates and follicles. Subsequently, signalling that might normally limit inflam-
mation could cascade. For example, TGF-β in the intestinal environment normally controls regulatory T cell 
development, however, in the presence of IL-1β , IL-6, IL-21 and IL-23 the emergence and maintenance of 
Diagnosis
Total number of 
calcein+ cells
Number of calcein+ PD-L1+ 
cells (% in brackets) NOD2 Genotype
Crohn’s disease
44 5 (11.4) Wild-type
19 0 (0) L1007fsincC
18 2 (11.1) G908R
5 0 (0) Wild-type
53 3 (5.7) R702W, G908R
38 2 (5.3) G908R
Carcinoma (controls)
17 14 (82.4) Wild-type
23 21 (91.3) Wild-type
7 7 (100) Wild-type
59 52 (88.1) Wild-type
17 17 (100) Wild-type
16 15 (93.8) Wild-type
10 10 (100) Wild-type
Ulcerative colitis (controls)
16 15 (93.75) Wild-type
26 26 (100) L1007fsincC
Table 1.  Nanomineral (calcein) positive and PD-L1 positive cell counts.
Figure 4. NAP induced PD-L1 expression in peripheral blood mononuclear cells of patients with Crohn’s 
disease is conserved. (A) Time-course of CD274 (encoding PD-L1) gene expression following an initial 3 hour 
exposure to particulate Pg (AMCP/sPG) in peripheral blood mononuclear cells from healthy (black; n = 4) and 
Crohn’s disease (red; n = 6) individuals. Timepoints represent the following: 0 = no stimulation; T3 = expression 
at end of 3 hour stimulation; T3 + 5 and T3 + 21; expression following, respectively, a further 5 hours and 
21 hours incubation in the control medium (i.e. absence of further stimulus). (B) PD-L1 (closed symbols) and 
PD-L2 (open symbols) surface expression following exposure to soluble Pg (sPg), particulate Pg (AMCP/sPg) 
and crude Pg (Pg) in CD14+ cells from healthy (black; n = 4) and Crohn’s disease (red; n = 6) donors. Data 
was obtained following a 3 hr stimulation and a further 21 hr incubation in control medium and is expressed 
as Mean ± SEM. Statistical significance of gene induction was calculated by repeated measurement one-way 
ANOVA with Dunnett’s multiple comparisons; and for protein expression levels using paired two-tailed t-tests. 
* p < 0.05, * * p < 0.01. Ctrl = Controls. CD = Crohn’s disease.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:26747 | DOI: 10.1038/srep26747
Th17 cells occurs29 and continuing inflammation may ensue. Restoring PD-L1 signalling in the NAP pathway 
would therefore present an interesting therapeutic option for the treatment of Crohn’s disease.
Materials and Methods
Analysis of intestinal CD274 gene and PD-L1 protein expression from public datasets. PD-L1 
is expressed from the CD274 gene (Gene ID 29126; RefSeq NM_014143). Potentially relevant studies for analysis 
were identified from the PubMed Database (access on 11/11/2013) using the search term: (whole genome OR 
transcriptom* OR gene array OR microarray OR PD-L1 OR CD274 OR B7-H1 OR PDCD1L1) AND (crohn* 
OR colitis OR ibd) AND (gut OR intestin* OR lamina propria OR peyer’s patch OR colon* OR ileum OR ileal OR 
bowel). Forty five studies (Supplementary Table 1) from 434 hits met our pre-defined inclusion criteria: (a) pub-
lished in English; (b) data on Crohn’s disease and controls; (c) intestine-derived samples from human subjects; 
(d) data on CD274 gene or PD-L1 protein expression, or global gene expression; and (e) original research. Two 
studies reported CD274 specific gene and/or PD-L1 protein data (Supplementary Table 2), while the rest provided 
whole genome expression data. Whole genome expression studies were excluded from further analysis if the data 
was not publicly accessible or did not contain CD274 expression data. Ultimately 22 publications from 11 unique 
datasets deposited on Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) or ArrayExpress (http://
www.ebi.ac.uk/arrayexpress/) were analysed further (Supplementary Table 3).
Where available, CD274 expression data was extracted using the web tool GEO2R, offered on Gene Expression 
Omnibus. GEO2R analyses yielded log2 fold changes (FC) which were manually converted into linear FC.
=
= − −
For positive log FC: linear FC 2
For negative log FC: linear FC 2
FC
FC
2
(log )
2
( log )
2
2
GEO2R analysis further returned the p value adjusted for multiple testing using Benjamini & Hochberg false 
discovery rate. If GEO2R analysis was not available, pre-processed raw data were accessed on GEO or down-
loaded from ArrayExpress, and manual calculations performed in Microsoft Excel 2010. Where necessary linear 
expression values were first log2 transformed. The log2 average expression value for each condition was used to 
calculate the fold change:
= −log FC (average expression patient) (average expression control)2
Log2 FC was then converted into linear FC as described above. The p value was calculated using a two-tailed 
student t-test, assuming equal variances.
Tissue Sections. Fresh anonymised lymphoid patch-containing human ileal tissue specimens used in this 
study were purchased from a commercial tissue bank (Tissue Solutions, UK) and held for use under HTA licence 
agreement 12383. Control samples were from the resection margins of patients with intestinal tumours (7 samples) 
or ulcerative colitis (2 samples), and Crohn’s disease samples (6 samples) were from patients with different disease 
anatomical locations (Supplementary Table 4). Following collection specimens were snap frozen and embed-
ded in Optimal Cutting Temperature compound. Tissue sections were subsequently cryo-sectioned at 14 μ m 
thickness, collected on SuperFrost® slides (Thermo Scientific, USA) and allowed to air dry for 1 hour at room 
temperature.
Immunohistochemistry. Immunohistochemical staining was undertaken in pairs (or multiples thereof) 
so that one Crohn’s disease section was always accompanied by a control section with identical staining. Prior 
to staining tissue sections were briefly fixed in 4% formaldehyde (Sigma-Aldrich, UK) for 10 to 15 min to pre-
vent sample degradation. Tissue sections were then blocked using 10% v/v goat serum, 1% w/v BSA, and 0.3 M 
Glycine. Sections were incubated with primary antibody [mouse anti-human PD-L1 (clone M1H1, eBiosci-
ence, USA); mouse anti-human glycoprotein 2 (MBL, USA); and mouse anti-peptidoglycan (clone 3F6B3, AbD 
Serotec, UK)], followed by incubation with secondary antibody (Alexa Fluor® 568 Goat Anti-mouse IgG [H + L], 
Invitrogen, UK) and stained for endogenous nanomineral using 0.01 M calcein (Sigma-Aldrich, UK). Nuclei were 
counterstained with ToPro-3 iodide (Invitrogen, UK) or Hoescht 33342 (Invitrogen, UK). Sections were mounted 
using ProLong® Gold Antifade Mountant (Invitrogen, UK).
Confocal microscopy. Confocal imaging was undertaken, at room temperature, in pairs (or multiples 
thereof) so that one Crohn’s disease section was always accompanied by a control section, and identical laser 
intensities were used. Detector gains for Crohn’s disease sections were set equal to, or higher than, that of the 
matched control ensuring that even faint PD-L1 staining above background could be detected for the former. 
Sections were imaged with a Leica DMIRE2 microscope (Leica Microsystems, Germany) at 488, 568 or 633 nm, 
fitted with diode Ar/ArKr and HeNe lasers, using either a x20, 0.7 NA multi-immersion lens or a x63, 1.2 NA 
water objective lens. Data were recorded using the Leica Confocal Software (v2.61) and images processed using 
ImageJ30. Data were collected as 8-bit greyscale images and subsequently assigned appropriate colours. Nuclei are 
shown grey to enable better visualisation of non-nuclear stains. Identical imaging and data collection routines 
were applied to Crohn’s disease and control sections. Three-dimensional representations were deconvoluted and 
reconstructed from z-stacks using Huygens Professional deconvolution software (SVI, The Netherlands).
Fluorescence Microscopy. Fluorescence imaging was undertaken, at room temperature using a Leica 
DMI6000B microscope with a x63, 0.7 NA water objective lens and images were captured using a Leica 
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DFC300FX camera. Data were recorded using the Leica Application Suite (v2.1.0R1) and images processed using 
ImageJ30. Data were collected as 8-bit greyscale images and subsequently assigned appropriate colours.
Determination of cell PD-L1 status. Overall PD-L1 expression in each lymphoid patch was determined 
by selecting the entire patch at 20x magnification and using ImageJ30 to quantify the mean fluorescence intensity 
in the red channel. PD-L1 status of calcein positive cells was examined on 63x micrographs. All cells showing 
clear calcein staining were selected, enlarged and their PD-L1 status determined; 3D stacks were used to assist 
determination in ambiguous cells (Supplementary Figure 2). As antibodies used for staining may adsorb to the 
nanomineral complexes6 cells that showed only overlapping signals from the intracellular calcein stain and the 
PD-L1 antibody were not considered PD-L1 positive. To be classed as PD-L1 positive clear evidence of separate 
PD-L1 staining was required (Supplementary Figure 2). Statistical differences were assessed with Mann-Whitney 
test using GraphPad Prism 6.03.
NOD2 Genotyping. DNA was extracted from tissue samples using Invitrogen’s PureLink Genomic DNA 
Mini Kit as per the manufacturer’s instructions. DNA concentration was measured using a NanoDrop spec-
trophotometer and fragments of the NOD2 gene amplified by PCR using an Abi 7500 Fast Real Time PCR 
instrument under the following conditions: 95 °C for 10 min, then 40–55 cycles of 95 °C for 15 seconds and 
60 °C for 1 min. The primers used were based on either published primer sets (G908R31) or custom designed 
primers as follows: R702Wfor+ M13 5-GTAAAACGACGGCCAGTTGCCCACGATGTGCATCC-3; 
R702Wrev+ M13 5-CAGGAAACAGCTATGACCGATGGAGTGGAAGTGCTTGC-3; L1007fsincC for 
5-CCTGCAGTCTCTTTAACTGG-3; and L1007fsincCrev 5-CTTACCAGACTTCCAGGATG-3. PCR amplicons 
were purified using Qiagen’s MinElute PCR Purification Kit and sequenced at the Department of Biochemistry, 
University of Cambridge.
Gene and protein expression in peripheral blood mononuclear cells. Peripheral blood mononu-
clear cells were isolated by density gradient centrifugation from healthy volunteers (n = 4) or Crohn’s disease 
patients heterozygotic for NOD2 polymorphisms (n = 6; R702W – 2 patients; G908R – 1 patient; L1007fsincC – 3 
patients). Cells were rested overnight prior to experimentation. Cell suspensions at 1 × 106 cells/ml were incu-
bated at 37 °C in 5% CO2 in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, penicillin 
(100 U/ml) and streptomycin (100 μ g/ml). Cells were stimulated with either 5 μ g/mL soluble E. Coli peptidogly-
can (sPg; Invivogen), 5 μ g/mL crude Pg from S.Aureus (Sigma-Aldrich), particulate Pg (AMCP/sPg – soluble Pg 
incorporated into AMCP particles), or culture media alone. After 3 hours cells were washed in HBSS (Sigma) and 
re-suspended in fresh culture media for a further 5 or 21 hours. Following incubation, cells were prepared for 
RNA extraction and CD274 gene expression analyses as previously described7. In parallel experiments, cells were 
also collected at 3 + 21 hours for analyses of PD-L1 and PD-L2 expression by flow cytometry. Cell pellets were 
stained with PD-L1 FITC (BD 558065) PD-L2 PE (BD 558066) and CD14 VioBlue (Miltenyi Biotec 130-094-
364), according to manufacturers’ instructions. Cells were washed and re-suspended in PBS containing 1% PFA 
and placed on ice in the dark until acquisition. Single stain and unstained compensation tubes were prepared to 
compensate for spectral overlap. Cells were acquired on a Cyan-ADP flow cytometer using Summit software for 
acquisition and analysis, acquiring a minimum of 450,000 events per sample.
Statistics. Statistical significance of gene induction was calculated by repeated measurement one-way 
ANOVA with Dunnett’s multiple comparisons; and for protein expression levels using paired two-tailed t-tests. 
Significance was taken as p < 0.05.
Ethics Statement. The study and experimental protocols were approved by the Cambridge National 
Research Ethics Committees (reference 03/296 and 05/Q0108/355) and carried out in accordance with approved 
guidelines. Peripheral blood mononuclear cells were isolated from the blood of recruited healthy volunteers or 
Crohn’s disease patients following written informed consent while, for the immunohistochemistry work, tissue 
sections were purchased anonymised from Tissue Solutions (a commercial tissue bank for which donors provide 
written informed consent).
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